Johnson & Johnson

Biocon shares surged 4% after its subsidiary, Biocon Biologics, received USFDA approval for YESINTEK (Ustekinumab-kfce), a biosimilar to Stelara used for treating Crohn’s disease, plaque psoriasis, ulcerative colitis, and psoriatic arthritis. The approval follows a settlement and licensing agreement with Janssen, allowing commercialization in the U.S. by February 2025.

Biocon Biologics Ltd's Yesintek, a biosimilar to Johnson & Johnson's Stelara, receives FDA approval for treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The approval aligns with a previously announced settlement and licensing agreement with Janssen Biotech Inc. and Johnson & Johnson.

The global psoriasis drug market is valued at US$ 14.08 billion in 2024, projected to grow at a CAGR of 6.9% to US$ 27.57 billion by 2034. Factors like smoking, alcohol, and cold temperatures increase psoriasis risk, driving market growth, especially in cold climates like the U.S. Key players include Amgen, Eli Lilly, and Novartis, focusing on strategic partnerships and product innovations. Corticosteroids are widely used for psoriasis treatment, prompting increased production by manufacturers.

Biocon Biologics Ltd announced FDA approval of YESINTEK™ (Ustekinumab-kfce), a biosimilar to Stelara®, for treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Previously, Biocon had settled with Janssen to commercialize YESINTEK™ in the U.S. no later than Feb 22, 2025.

Biocon Biologics' Yesintek (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab), has been approved by the FDA for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The approval follows a settlement and licensing agreement with Janssen to commercialize Yesintek in the U.S. by February 22, 2025.

Biocon shares rose 4% after U.S. FDA approved Yesintek, a biosimilar to J&J's Stelara. Yesintek treats Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Biocon's stock has gained 47% YTD, outperforming Nifty 50's 11% rise. Biocon reported an 84% YoY decline in Q2 net profit to Rs 27 crore, with revenue up 4% to Rs 3,590 crore. EBITDA fell 7.6% YoY to Rs 685.5 crore, with margin narrowing to 19.1%.

Biocon's share price surged 4% on FDA approval for biosimilar Yesintek, targeting chronic conditions like Crohn's disease. The approval positions Biocon competitively in the global biosimilars market, with a settlement and licensing agreement allowing U.S. commercialization from 2025. Financial results showed mixed performance, with a net profit decline but revenue growth. The stock's candlestick pattern indicates market indecision, with potential bullish or bearish strategies based on price movements.

Biocon Biologics Ltd announced FDA approval of YESINTEK (Ustekinumab-kfce), a biosimilar to Stelara, for treating Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis. The company had previously settled with Janssen to commercialize YESINTEK in the U.S. by February 2025.

Biocon Biologics receives FDA approval for biosimilar YESINTEK (Ustekinumab-kfce), set to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The biosimilar will be commercialized in the US by February 2025 under a licensing agreement with Janssen.

FDA approves Yesintek (ustekinumab-kfce), a biosimilar to Stelara, for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Yesintek carries risks of infections, malignancies, hypersensitivity reactions, and other adverse effects.